Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 8.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,079 shares of the medical research company’s stock after selling 389 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Amgen were worth $966,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Moody National Bank Trust Division purchased a new position in shares of Amgen in the 4th quarter valued at $200,000. Magnus Financial Group LLC grew its position in shares of Amgen by 12.1% in the 4th quarter. Magnus Financial Group LLC now owns 1,735 shares of the medical research company’s stock valued at $418,000 after buying an additional 187 shares during the last quarter. DT Investment Partners LLC grew its position in shares of Amgen by 6.8% in the 4th quarter. DT Investment Partners LLC now owns 24,096 shares of the medical research company’s stock valued at $5,809,000 after buying an additional 1,534 shares during the last quarter. Sageworth Trust Co purchased a new position in shares of Amgen in the 4th quarter valued at $42,000. Finally, M&G Investment Management Ltd. purchased a new position in shares of Amgen in the 4th quarter valued at $4,417,000. 76.69% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Amgen in a research report on Monday, October 14th. They issued an “outperform” rating on the stock. Credit Suisse Group increased their target price on shares of Amgen from $235.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, December 13th. Leerink Swann increased their target price on shares of Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Evercore ISI raised shares of Amgen from an “in-line” rating to an “outperform” rating in a research report on Tuesday, January 21st. Finally, Cowen increased their price target on shares of Amgen from $253.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $240.11.
In other news, EVP Jonathan P. Graham sold 9,000 shares of Amgen stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $230.54, for a total transaction of $2,074,860.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David W. Meline sold 8,737 shares of Amgen stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $234.36, for a total transaction of $2,047,603.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,162 shares of company stock valued at $4,214,030. Insiders own 0.25% of the company’s stock.
NASDAQ:AMGN opened at $224.84 on Wednesday. The company has a current ratio of 2.89, a quick ratio of 2.59 and a debt-to-equity ratio of 2.54. The firm has a 50-day moving average price of $238.31 and a two-hundred day moving average price of $211.98. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $244.99. The company has a market capitalization of $134.04 billion, a P/E ratio of 15.44, a price-to-earnings-growth ratio of 1.95 and a beta of 1.11.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.13. Amgen had a net margin of 34.48% and a return on equity of 80.26%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. During the same period last year, the firm posted $3.69 EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. On average, equities research analysts predict that Amgen, Inc. will post 14.63 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.60 per share. The ex-dividend date of this dividend is Thursday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $1.45. This represents a $6.40 dividend on an annualized basis and a dividend yield of 2.85%. Amgen’s payout ratio is 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Most Volatile Stocks
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.